DAVID C YOUNG portrait
  • Multi-state Pharmacy Jurisprudence Examination (MPJE) Committee, National Association of Boards of Pharmacy (NABP)
  • Vice Chair, Pharmacotherapy
  • Utah Asthma Task Force, Utah Department of Health
  • Controlled Substances Advisory Committee, Division of Occupational & Professional Licensing (DOPL)
  • Cystic Fibrosis Related Diabetes (CFRD) Guideline Committee, Cystic Fibrosis Foundation
  • Coordinator of Student Affairs, College Of Pharmacy
  • Adjunct Professor, Physical Therapy & Athletic Training
  • Professor, Pharmacotherapy
  • Professor (Clinical), Pharmacotherapy
801-581-8510

Research Keywords

  • Rhinitis, Allergic, Perennial
  • Pulmonary Disease, Chronic Obstructive
  • GERD
  • Cystic Fibrosis
  • Asthma, Exercise-Induced
  • Asthma Management
  • Asthma
  • Anti-Asthmatic Agents

Presentations

  • “Spring 2024 Utah Pharmacy Legislative Session Update” Presented at Academy of Managed Care Pharmacy Utah Chapter, Salt Lake City, Utah (0128-9999-24-019-L03-P, 0128-9999-24-019-L03-T, 1 hr). Presentation, Presented, 03/2024.
  • “Clinical Pearls 2023-Breakthroughs in Asthma Control: Harnessing the Power of Biologic Therapies to Control Severe Asthma,” Presented at ASHP Midyear Clinical Meeting. Anaheim, CA (ACPE 0204-0000-23-289-L01-P, 2hrs). Presentation, Presented, 12/2023.
  • Jacobs H, Bhakta Z, Packer K, Liou TG, Young DC. Minimum inhibitory concentration targeted antibiotic dose optimization in people with cystic fibrosis. European Cystic Fibrosis Conference; Vienna, Austria;. Other, Presented, 06/2023.
  • Venkata KY, Lindley B, Radetich E, Kumar S, Bhakta Z, Leclair L, Young DC. Population Pharmacokinetics of Intermittent Vancomycin in Cystic Fibrosis Patients. Population Approach Group in Europe (PAGE) Meeting. Coruña, Spain;. Other, Presented, 06/2023.
  • “Spring 2023 Utah Pharmacy Legislative Session Update” Presented at Academy of Managed Care Pharmacy Utah Chapter, Salt Lake City, Utah (0128-9999-23-019-L03-P, 0128-9999-23-019-L03-T, 1 hr). Presentation, Presented, 03/2023.
  • “Recent Advancements in the Management of Cystic Fibrosis: The Role of Health System Pharmacists,” Presented at PTCE Webinar (ACPE 0290-0000-22-350-L01-P, 1.5hrs) September 12, 2022 – November 13, 2022. Presentation, Presented, 09/2022.
  • “Pulmonary Device Workshop” Presented at the W.A.T.S. (Wednesday Afternoon Teaching Session), Department of Family and Preventative Medicine, University of Utah, Salt Lake City, Utah. Presentation, Presented, 08/2022.
  • “COPD Update” Presented at the W.A.T.S. (Wednesday Afternoon Teaching Session), Department of Family and Preventative Medicine, University of Utah, Salt Lake City, Utah. Presentation, Presented, 08/2022.
  • “Spring 2022 Utah Pharmacy Legislative Session Update” Presented at Academy of Managed Care Pharmacy Utah Chapter, Salt Lake City, Utah (0128-9999-22-019-L03-P, 0128-9999-22-019-L03-T, 1 hr). Presentation, Presented, 03/2022.
  • “CF Team Pharmacy: Past, Present, and Future Directions,” Presented at the North American Cystic Fibrosis Conference. Virtual (Pharmacist Caregiver Session Speaker). Presentation, Presented, 11/2021.
  • “Pharmacy Law Update 2021” Presented at Utah Pharmacy Association Mid-year meeting, Salt Lake City, Utah (0107-9999-21-344-L03-P, 0107-9999-21-344-L03-T, 1.5 hr). Presentation, Presented, 10/2021.
  • Pharmacy Based Immunization Delivery—A certificate program for pharmacists” Presented at the University of Utah College of Pharmacy, Salt Lake City, Utah (ACPE 0202-0000-20-179-H06-P, 8hrs). Presentation, Presented, 09/2021.
  • “Utah AMCP 2021 Virtual Legislative Update” Presented at Academy of Managed Care Pharmacy Utah Chapter, Salt Lake City, Utah (0128-9999-21-019-L03-P, 0128-9999-21-019-L03-T, 1 hr). Presentation, Presented, 04/2021.
  • “Understanding the Expanding Role of Pharmacy Services in Outpatient CF Care: What Can Team Rx Do 4U” Presented at Utah Pharmacy Association Annual Meeting (0107-9999-21-168-L01-P, 0107-9999-21-168-L01-T, 1.5hr). Presentation, Presented, 04/2021.
  • Abbinanti, A, Witt, D, Saunders J, Jones A, Young DC. Venous Thromboembolism Management In Patients With Cystic Fibrosis. North American Cystic Fibrosis Foundation Conference, Virtual, October 2020. Other, Presented, 10/2020.
  • Gabriel C, Zobell JT, Jacobs H, Bhakta Z, Young DC. Survey of Cystic Fibrosis Foundation Accredited Care Centers and Affiliate Programs Regarding Antibiotic Utilization For The Treatment Of Mycobacterium Abscessus Infection. North American Cystic Fibrosis Foundation Conference, Virtual. Other, Presented, 10/2020.
  • Wiederrich J, Sakon C, Bhakta Z, Watanabe A, Young D. Acute Kidney Injury In Cystic Fibrosis Patients Treated With Two Intravenous Colistin Dosing Regimens. North American Cystic Fibrosis Foundation Conference, Virtual;. Other, Presented, 10/2020.
  • “Impact of Pharmacy Care on Patients and Families,” Presented at the North American Cystic Fibrosis Conference. Virtual (Pharmacist Symposium Session Speaker). Presentation, Presented, 10/2020.
  • “Pharmacy Based Immunization Delivery—A certificate program for pharmacists” Presented at the University of Utah College of Pharmacy, Salt Lake City, Utah (ACPE 0202-0000-20-180-L06-P, 8hrs). Presentation, Presented, 09/2020.
  • Gabriel C, Zobell JT, Jacobs H, Bhakta Z, Young DC. Survey of Cystic Fibrosis Foundation Accredited Care Centers and Affiliate Programs Regarding Antibiotic Utilization For The Treatment Of Mycobacterium Abscessus Infection. Mountain States Residency Conference, Salt Lake City, UT. Other, Presented, 05/2020.
  • “Cystic Fibrosis Module #2: Chronic Medications: Changing the Course of Cystic Fibrosis,” Presented at NASP/CSPE Webinar (ACPE 0221-9999-20-213-H01-P, 0.75hrs, May 15, 2020 – May 15, 2023). Presentation, Presented, 05/2020.
  • “Cystic Fibrosis Module #4: Adherence, Access, Education: Current Challenges and Overcoming Barriers in CF Medications,” Presented at NASP/CSPE Webinar (ACPE 0221-9999-20-215-H01-P, 0.75hrs, May 15, 2020 – May 15, 2023). Presentation, Presented, 05/2020.
  • Watanabe AH, Willis C, Ragsdale R, Moore K, Kukreja P, Amarasinghe, Klein A, Brixner D, Young DC. Development and Analysis of a Novel Digital Health App Designed for Cystic Fibrosis. Academy of Managed Care Pharmacy Annual Meeting, Houston,TX. Other, Presented, 04/2020.
  • “Optimization of Anti-pseudomonal Antibiotics in CF Pulmonary Exacerbations,” Presented at Royal Brompton Hospital Grand Rounds. London, United Kingdom (Grand Rounds speaker). Presentation, Presented, 04/2017.
  • “The Challenge of Emerging Organisms in CF,” Presented at Australasian Cystic Fibrosis Conference. Sydney, Australia (Symposium Speaker). Presentation, Presented, 08/2015.
  • “Abscessus: The Emerging Nemesis,” Presented at Australasian Cystic Fibrosis Conference. Sydney, Australia (Symposium Speaker). Presentation, Presented, 08/2015.
  • “Antimicrobial Treatment including aminoglycoside monitoring,” Presented at Australasian Cystic Fibrosis Conference. Sydney, Australia (Symposium Speaker). Presentation, Presented, 08/2015.
  • “Value of a dedicated CF Pharmacist,” Presented at Australasian Cystic Fibrosis Conference. Sydney, Australia (Symposium Speaker). Presentation, Presented, 08/2015.
  • “Optimization of Antibiotics in CF Pulmonary Exacerbations,” Presented at Australasian Cystic Fibrosis Conference. Sydney, Australia (Symposium Speaker). Presentation, Presented, 08/2015.

Grants, Contracts & Research Gifts

  • Implementation of tablet-based audiology screening protocol in CF patients. PI: McKinzie C. Co-PI(s): Tak C, Kam C, Elson C, Sapp C, Stoudemire W, Kimple A, Leandro J, Jones M, Young DC. Cystic Fibrosis Foundation (CFF), 01/2023 - present. Total project budget to date: $374,959.00
  • Implementation of Outpatient Clinical Pharmacy Award for A Pharmacist and/or Pharmacy Technician Services at CFF-accredited care centers and affiliate programs. PI: David C. Young. Cystic Fibrosis Foundation (CFF), 01/2016 - present. Total project budget to date: $135,000.00
  • Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Adult Patients with Cystic Fibrosis. PI: Paul Beringer, PharmD. Co-PI(s): Joanne Billings, MD; Adupa P. Rao, MD; David C. Young, Pharm.D. . Foundation for the National Institutes of Health (fNIH), 01/2014 - 12/2019. Total project budget to date: $235,000.00
  • Impact of individualized, pharmacist-provided asthma education in an Asthma Care Pharmacy. PI: Young DC, Pharm.D. Co-PI(s): Zobell J, Pharm.D.; Jorgensen R,; Jennings B, Pharm.D.; Wagner D, Pharm.D.; Jolley T, RPh; Atherton A, Pharm.D.; Fitzpatrick R, RPh; Samuelson W, M.D. . Marriner S Eccles Foundation, 01/2009 - 01/2013. Total project budget to date: $6,500.00
  • Comparative Effectiveness of Dual Bronchodilation for Treatment of Chronic Obstructive Pulmonary Disorder (COPD) in a Usual-Care Setting. PI: Asche Carl V. Co-PI(s): Young David, Yu Junhua, Ye Xiangyang, Oberg Brian. Novartis Pharmaceuticals, 01/2007 - 12/2013. Total project budget to date: $299,798.00
  • Elucidation of Acid-Induced Pulmonary Inflammation. PI: Peterson K. Co-PI(s): Samuelson W, Go M, Young DC, Sturrock A, Kuwada S, Ryujin D. Tap Pharmaceutical Products Inc., 01/2007 - 12/2010. Total project budget to date: $111,345.00
  • COPD: Impact of Intervention on Compliance to the recommended HEDIS guidelines, Clinical Outcomes and Cost of Illness. PI: Asche C. Co-PI(s): Brixner D, Young D. Boehringer-Ingelheim, 01/2006 - 12/2013. Total project budget to date: $153,000.00
  • Effect of Acid Reflux on Respiratory Physiology during Exercise in Athletes with GER-Response to Acid Suppression. PI: Peterson K. Co-PI(s): Ryujin D, Mannebach S, Samuelson W, Fang J, Young DC. AstraZeneca Pharmaceuticals, 01/2006 - 12/2009. Total project budget to date: $105,400.00
  • Pharmacokinetics of standard versus high doses of salmeterol in adult cystic fibrosis patients. PI: Young DC. Co-PI(s): Liou T, Carveth H, Clark T, Jensen J, Wilkins D, Mannebach S, Noland B, Huang D, Munger M. GCRC Grant no. M01-RR00064 from the National Center for Research Resources, 01/2004 - 12/2008. Total project budget to date: $35,000.00
  • A pilot study: Impact of individualized, pharmacist-provided asthma education in an adult asthma clinic. PI: Young DC. Co-PI(s): Samuelson WM, Sullivan CA. Astra-Zeneca, 01/2000 - 12/2001. Total project budget to date: $2,500.00
  • Chronically inhaled salmeterol improves pulmonary function in heart failure. PI: Ng TM. Co-PI(s): Munger MA, Lombardi WL, Doing TH, Ryujin DT, Young DC, Lugo RA. Public Health Service Research Grant-in-Aid M01-RR00064 National Center for Research Resources, 01/1999 - 12/2000. Total project budget to date: $10,600.00

Research Interests

Dr. Young is the clinical pharmacist at the University of Utah Adult Cystic Fibrosis and Asthma Centers. Dr. Young is a member of the Cystic Fibrosis Foundation (CFF) Clinical Research, and CFF Infection Research Initiative Review Committees. Dr. Young is the Director of the CFF Implementation of Outpatient Pharmacy Services and Co-director of the CFF Pharmacist Mentorship Programs. Dr. Young is a member of the National Association of Boards of Pharmacy Multistate Pharmacy Jurisprudence Examination (MPJE) Committee. Dr. Young is a member of the Division of Occupational & Professional Licensing Utah Physician and Surgeon Licensing Board. Dr. Young is the program coordinator for PGY-2 Internal Medicine Pharmacy Residency at the University of Utah Health. Dr. Young is actively engaged in research regarding improving care for patients with cystic fibrosis and asthma.

Languages

  • English, fluent.

Publications

  • Sherwood SJ, Tak C, Bhakta ZN, Packer K, Jacobs H, Liou TG, Young DC. A comparison of aminoglycoside antibiotic serum concentrations collected by peripheral veins and peripherally inserted central catheters in adults with cystic fibrosis. Pediatr Pulmonol. 2024 Jun;59(6):1740-1746. https://doi:10.1002/ppul.26986. Epub 2024 Mar 19. PubMed PMID: 38501330. Published, 06/2024.
  • Yellepeddi VK, Lindley B, Radetich E, Kumar S, Bhakta Z, Leclair L, Parrot M, Young DC. Population Pharmacokinetics and Target Attainment Analysis of Vancomycin after Intermittent Dosing in Adults with Cystic Fibrosis. Antimicrob Agents Chemother. 2023 Dec 7:e0099223. https://doi.org/10.1128/aac.00992-23 Online ahead of print. PMID: 38059634. Published, 12/07/2023.
  • Grube PM, Autry EB, Kormelink LN, Young DC, Zobell JT, Bhakta ZN, Schadler AD, Kuhn RJ. A Decade of Change: The Evolution of Pharmacy Services at U.S. Cystic Fibrosis Centers. Pediatr Pulmonol. 2023 Dec 5. https://doi.org/10.1002/ppul.26798. Online ahead of print. PMID: 38050809. Published, 12/05/2023.
  • Abbinanti A, Witt DM, Saunders J, Jones AE, Young DC. Venous thromboembolism management in people with cystic fibrosis. Pediatr Pulmonol. 2023;1-8. http://doi.org/10.1002/ppul.26786 Epub 2023 November 17.. Published, 11/17/2023.
  • Lindley B, Bhakta Z, Leclair L, Young DC. The Pharmacokinetics of Continuous Infusion Vancomycin in Adult People with Cystic Fibrosis. Pediatr Pulmonol. 2024;59:89–94. http://doi.org/10.1002/ppul.26714. Epub 2023 October 4. Published, 10/04/2023.
  • Young DC, Gadd S, Ashmead P, Abbinanti A, Pinnock E, Lam T, Turner K. Assessing the impact of a leadership and advocacy elective course in a college of pharmacy curriculum. Currents in Pharmacy Teaching and Learning. 2023 Sep;15(9):843-847. https://doi.org/10.1016/j.cptl.2023.07.016. Epub 2023 Aug 3. Published, 09/2023.
  • Veettil SK, Vincent V, Shufelt T, Behan E, Syeed M, Thakkinstian A , Young DC , Chaiyakunapruk N. Incremental Net Monetary Benefit of Biologic Therapies in Moderate to Severe Asthma: A Systematic Review and Meta-Analysis of Economic Evaluation Studies. J Asthma. 2023 Feb 24;1-25. https://doi.org/10.1080/02770903.2023.2183407. PMID: 36825403. Published, 02/2023.
  • McKinzie CJ, Kam C, Zobell JT, Young DC. Effective pharmacy provider handoff communication for patient care in CF. Pediatr Pulmonol. 2023;58:2394‐2395 https://doi:10.1002/ppul.26464. Published, 01/2023.
  • Hong L, Downes K, FakhriRavari A, Abdul-Mutakabbir J, Kuti J, Jorgensen S, Young DC, Alshaer M, Bassetti M, Bonomo R, Gilchrist M, Jang S, Lodise T, Roberts J, Tangden T, Zuppa A, Scheetz M. International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2023;43:736-739. https://doi.org/10.1002/phar.2844. Published, 01/2023.
  • Hong L, Downes K, FakhriRavari A, Abdul-Mutakabbir J, Kuti J, Jorgensen S, Young DC, Alshaer M, Bassetti M, Bonomo R, Gilchrist M, Jang S, Lodise T, Roberts J, Tangden T, Zuppa A, Scheetz M. International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2023;43:740–777. https://doi.org/10.1002/phar.2842. Published, 01/2023.
  • Young D.C. (2023). Cystic Fibrosis. In E. Alderman (Eds.), Pharmacotherapy Self-Assessment Program: Pulmonary and Gastrointestinal Diseases Book (pp. 51-80). Pharmaceutical Education Publications. Published, 01/2023.
  • Watanabe AH, Willis C, Ragsdale R, Biskupiak J, Moore K, Brixner D, Young D. Patient perspectives on the Use of Digital Technology to Help Manage Cystic Fibrosis. Pulmonary Medicine 2023 Jan; 2023:1-7. https://doi.org/10.1155/2023/5082499. Published, 01/2023.
  • Lindley B, Bhakta Z, Gray K, Watanabe A, Leclair L, Young DC. Pharmacokinetics of intermittent dosed intravenous vancomycin in adult persons with cystic fibrosis. Pediatr Pulmonol. 2022. 1-6. https://doi.org/10.1002/ppul.26077 Epub 2022 July 14. Published, 07/14/2022.
  • Heo S, Young DC, Safirstein J, Bourque B, Antell MH, Diloreto S, Rotolo SM. Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy. J Cyst Fibros. 2022 Mar;21(2):339-343. https://doi.10.1016/j.jcf.2021.10.002. Epub 2021 Nov 3. PMID: 34742667. Published, 03/2022.
  • Grant JJ, McDade EJ, Zobell JT, Young DC. The indispensable role of pharmacy services and medication therapy management in cystic fibrosis. Pediatr Pulmonol. 2022 Feb;57 Suppl 1:S17-S39. https://doi:10.1002/ppul.25613. Epub 2021 Aug 11. PMID: 34347382. Published, 02/2022.
  • Pharmacokinetics and pharmacodynamics of intermittent and continuous infusion of vancomycin in adult cystic fibrosis patients. B. Lindley, Z. Bhakta, K. Gray, H. Jacobs, A. Watanabe, L. Leclair, D. Young. J. Cyst. Fibros. 2021 Nov; 20(2):S 123. https://doi.org/10.1016/S1569-1993(21)01677-5. Published, 11/2021.
  • Epps QJ, Epps KL, Young DC, Zobell JT. State of the art in cystic fibrosis pharmacology optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: III. Executive summary. Pediatr Pulmonol. 2021;56:1825–1837. https://doi.org/10.1002/ppul.25353. Epub 2021 Mar 3. Published, 03/03/2021.
  • Zobell JT, Moss J, Heuser S, Roe L, Young DC. Understanding the expanding role of pharmacy services in outpatient cystic fibrosis care. Pediatr Pulmonol. 2021;56:1378-1385. https://doi-org.ezproxy.lib.utah.edu/10.1002/ppul.25283 Epub 2021 Feb 1. Published, 02/01/2021.
  • Epps QJ, Epps KL, Zobell JT, Young DC. Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: II. Therapies for allergic bronchopulmonary aspergillosis. Pediatr Pulmonol. 2020;55:3541 3572.https://doi.org/10.1002/ppul.25080 Epub 2020 Sept 18. Published, 09/18/2020.
  • Zobell JT, Moss J, Heuser SM, Asfour F. (Acknowledgements David Young). Impact of pharmacy technicians as part of an integrated health‐system pharmacy team on improvement of medication access in the care of cystic fibrosis patients. Pediatr Pulmonol. 2020;55:3351-3357. https://doi.org/10.1002/ppul.25050 Epub 2020 Sept 2. Published, 09/02/2020.
  • Abbinanti, A, Witt, D, Saunders J, Jones A, Young DC. Venous Thromboembolism Management In Patients With Cystic Fibrosis. Pediatr Pulmonol. 2020;55(S2):245-246. Published, 01/2020.
  • Wiederrich J, Sakon C, Bhakta Z, Watanabe A, Young D. Acute Kidney Injury In Cystic Fibrosis Patients Treated With Two Intravenous Colistin Dosing Regimens. Pediatr Pulmonol. 2020;55(S2):245. Published, 01/2020.
  • Gabriel C, Zobell JT, Jacobs H, Bhakta Z, Young DC. Survey of Cystic Fibrosis Foundation Accredited Care Centers and Affiliate Programs Regarding Antibiotic Utilization For The Treatment Of Mycobacterium Abscessus Infection. Pediatr Pulmonol. 2020;55(S2):245. Published, 01/2020.
  • Stults BM, Dunson WM, Young DC. Management of Hypertension in Diabetes Mellitus. In: Jones RE, Kulkarni K, editors. Utah Diabetes Management Handbook. 2nd ed. Salt Lake City: Buckboard Press; 2002 p. 25.1-25.10. Published, 01/2002.
  • Young, DC. Review of New Drugs for Asthma, Allergy, and COPD. Basel, by Trevor J Hansel and Peter J Barnes. Resp Care 2002;47(12):1479-1480. Published, 01/2002.

Copyrights

  • Providers United For Improving Inhaler Technique (PUFIIT SCALE) (Submitted to Library of Congress). 05/2003.